Therapeutic Response

BRAF p.V600E status confers therapeutic sensitivity to Dabrafenib in combination with Trametinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Mekinist (trametinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.
Tafinlar (dabrafenib) [product information]. EMA. The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.
Mekinist (trametinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.
Tafinlar (dabrafenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.